Martin Dietrich, MD, PhD

Articles

Final Thoughts on the Treatment of EGFR-Mutant NSCLC: Balancing Safety and Efficacy, and the Importance of Incorporating Supportive Care Strategies

May 23rd 2025

Panelists discuss how implementing the new standard of combination therapies requires thorough patient education, prophylactic management of toxicities, and multidisciplinary support to optimize outcomes for patients with EGFR-mutant lung cancer.

The Future of Biomarkers in EGFR-Mutant NSCLC: Sequencing Strategies and Optimizing Patient Time on Treatment

May 23rd 2025

Panelists discuss how optimizing treatment duration, using local therapy for oligometastatic disease, and understanding the limitations of current biomarkers are important considerations in developing effective sequencing strategies for EGFR-mutant lung cancer.

Treatment Options in the Second-Line for CNS Protection In EGFR-Mutant NSCLC

May 23rd 2025

Panelists discuss how central nervous system (CNS) progression presents unique challenges in treatment decision-making, highlighting the importance of brain imaging surveillance and considering approaches that maintain CNS disease control while addressing systemic progression.

The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC

May 16th 2025

Panelists discuss how many patients never receive second-line therapy, emphasizing the critical importance of selecting the optimal first-line treatment and monitoring patients closely to identify progression early.

Disease Reassessment at First Progression and Treatment Options for Resistance Mechanisms in EGFR-mutant NSCLC

May 16th 2025

Panelists discuss how subsequent therapy after initial disease progression should consider patient symptomatology, biomarker testing through tissue or liquid biopsies, and potential treatment options including MET-targeted approaches or chemotherapy combinations.

The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC

May 9th 2025

Panelists discuss how quality of life considerations, including prophylactic medications to prevent dermatologic toxicities and infusion-related reactions, are crucial when implementing EGFR-targeted therapies, especially the MARIPOSA regimen.

Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC

May 9th 2025

Panelists discuss how the overall survival benefit from the MARIPOSA regimen (amivantamab plus lazertinib) with a hazard ratio of 0.75 and projected survival improvement exceeding 1 year represents a significant advancement that must be weighed against toxicity concerns.

Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective

April 28th 2025

Panelists discuss how conversations with patients about treatment options have become more complex and nuanced, requiring thorough explanation of efficacy data and adverse effects while adapting to each patient’s level of understanding and involvement.

Combination Therapy: A New Frontline Standard in the Treatment of EGFR-Mutant NSCLC

April 28th 2025

Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved with new combination therapies like osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA) challenging osimertinib monotherapy as the standard of care.

Unmet Needs in LCNEC

January 13th 2025

Panelists discuss what they would like to see in future trials to address the unmet needs and challenges in treating patients diagnosed with lung large cell neuroendocrine carcinoma (LCNEC).

Potential Next-Generation Therapies for Lung LCNEC

January 6th 2025

Panelists discuss any upcoming trials on the horizon that they are excited about in the context of lung large cell neuroendocrine carcinoma (LCNEC) treatment.

Insights Into Ongoing Investigational Studies in Lung LCNEC

January 6th 2025

Panelists discuss ongoing lung large cell neuroendocrine carcinoma (LCNEC) trials involving both familiar and novel agents, including phase 2 durvalumab + EP (1L), phase 2 LCNEC-ALPINE atezolizumab + EP (1L), phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific antibody (2L+), and phase 1 LB2102 DLL2-directed CAR T (2L+).

Overview of Studies of BI 764532 for Lung LCNEC

December 30th 2024

Panelists discuss ongoing trials with BI 764532 and their potential impact on the treatment of lung large cell neuroendocrine carcinoma (LCNEC).

Novel Targeted Therapies for LCNEC of the Lung

December 30th 2024

Panelists discuss how novel targeted therapies, such as T-cell engagers, could improve outcomes for patients with lung large cell neuroendocrine carcinoma (LCNEC) and other neuroendocrine cancers (NECs).

Insights on the LANCE Pilot Study on Lung LCNEC

December 23rd 2024

Panelists discuss their impressions of the LANCE pilot study for atezolizumab in lung large cell neuroendocrine carcinoma (LCNEC) and its potential impact on treatment strategies.

The Role of DLL3 in LCNEC of the Lung

December 23rd 2024

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

Lung LCNEC Disease Histology and Prognosis

December 16th 2024

A Multidisciplinary Approach to Managing Lung LCNEC

December 16th 2024

Panelists discuss the vital multidisciplinary coordination needed to optimize care for patients with lung large cell neuroendocrine carcinoma (LCNEC), including the roles of various specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the importance of involving the patient in these discussions.

Lung LCNEC Diagnostic Challenges

December 9th 2024

Panelists discuss the challenges encountered with molecular or pathology testing for lung large cell neuroendocrine carcinoma (LCNEC) and how treatment plans are determined when testing is not feasible.

Biopsy Best Practices: Diagnosing Lung LCNEC

December 9th 2024

Panelists discuss the factors that influence the decision to perform a fine needle aspirate vs an incisional biopsy, whether testing is conducted in-house or at a central laboratory, and how the results of these tests impact the treatment plan for patients with lung large cell neuroendocrine carcinoma (LCNEC).